Bioventus Inc (BVS) - Total Liabilities
Based on the latest financial reports, Bioventus Inc (BVS) has total liabilities worth $455.11 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Bioventus Inc (BVS) cash conversion ratio to assess how effectively this company generates cash.
Bioventus Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Bioventus Inc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Bioventus Inc to evaluate the company's liquid asset resilience ratio.
Bioventus Inc Competitors by Total Liabilities
The table below lists competitors of Bioventus Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Peet Ltd
AU:PPC
|
Australia | AU$403.77 Million |
|
Sinopec Shandong Taishan Petroleum Co Ltd
SHE:000554
|
China | CN¥673.27 Million |
|
Beijing Beetech Inc
SHE:300667
|
China | CN¥300.22 Million |
|
United Faith Auto-Engineering Co. Ltd.
SHE:301112
|
China | CN¥229.39 Million |
|
MNTN, Inc.
NYSE:MNTN
|
USA | $72.57 Million |
|
Shanghai Material Trading Co Ltd A
SHG:600822
|
China | CN¥551.18 Million |
|
Huatian Hotel Group Co Ltd
SHE:000428
|
China | CN¥3.65 Billion |
|
Fitipower Integrated Technology Inc
TW:4961
|
Taiwan | NT$3.76 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Bioventus Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BVS market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioventus Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioventus Inc (2014–2025)
The table below shows the annual total liabilities of Bioventus Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $455.11 Million | -16.09% |
| 2024-12-31 | $542.35 Million | -8.04% |
| 2023-12-31 | $589.79 Million | -38.59% |
| 2022-12-31 | $960.43 Million | +38.78% |
| 2021-12-31 | $692.07 Million | +97.56% |
| 2020-12-31 | $350.31 Million | +7.20% |
| 2019-12-31 | $326.79 Million | +9.86% |
| 2018-12-31 | $297.46 Million | +0.83% |
| 2015-12-31 | $295.01 Million | +16.64% |
| 2014-12-31 | $252.93 Million | -- |
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis… Read more